Created on Sunday, 26 March 2023 14:33
by Alan M Dattner, MD doctordattner@gmail.com
I was excited to see the studies that showed a 32-fold increase in MS in recruits who became EBV positive[i]. Howard Weiner at Harvard has described targeting EBV to treat MS.[ii] Over 200 articles on PubMed discuss the link between EBV and MS. NexImmune’s project to grow T-cells that destroy EBV infected B-cells[iii], also point to the potential value of treating EBV as a method of controlling MS. EBV appears to incite a cross-reactive attack by EBV protein EBNA against similar molecules related to nerve cells and the myelin sheath such as GlialCAM. [iv] Many other articles discuss EBV and cross-reactive antigens on related to nerve and brain tissue.
My interest was stimulated because I had developed a series of methods to treat severe autoimmune skin and generalized conditions that included targeting EBV with a combination of intestinal microbiome modifiers, as well as a diet and supplements to restore integrity of the intestinal barrier and inhibit EBV. I realized that this treatment program would likely be applicable to treating patients with MS and high levels of EBV reactivity.
#EpsteinBarrVirus #EBV #MultipleSclerosis #MS #Neurology